
Literaturverzeichnis

1. Symmons DP: Epidemiology of rheumatoid arthritis: determinants of onset, persistence and outcome. *Best Pract Res Clin Rheumatol* 2002; 16:707–722.
Rec# 323
2. Young A, Dixey J, Cox N, Davies P, Devlin J, Emery P, Gallivan S, Gough A, James D, Prouse P, Williams P, Winfield J: How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results of 5 years of follow-up in 732 patients from the Early RA Study (ERAS). *Rheumatology (Oxford)* 2000; 39:603–611.
Rec# 4
3. Wolfe F, Zwillich SH: The long-term outcomes of rheumatoid arthritis: a 23-year prospective, longitudinal study of total joint replacement and its predictors in 1600 patients with rheumatoid arthritis. *Arthritis Rheum* 98; 41:1072–1082.
Rec# 1
4. Emery P: Therapeutic approaches for early rheumatoid arthritis. How early? How aggressive? *Br J Rheumatol* 95; 34 Suppl 2:87–90.
Rec# 8
5. Machold KP, Eberl G, Leeb BF, Nell V, Windisch B, Smolen JS: Early arthritis therapy: rationale and current approach. *J Rheumatol Suppl* 98; 53:13–19.
Rec# 9
6. O'Dell JR: Treating rheumatoid arthritis early: a window of opportunity? *Arthritis Rheum* 2002; 46:283–285.
Rec# 225
7. Boers M: Understanding the window of opportunity concept in early rheumatoid arthritis. *Arthritis Rheum* 2003; 48:1771–1774.
Rec# 324
8. Scottish Intercollegiate Guidelines Network: Management of early rheumatoid Arthritis. 2001
Rec# 332
9. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum* 88; 31:315–324.
Rec# 16
10. Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JM: How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. *Arthritis Rheum* 2002; 46:357–365.
Rec# 233
11. Bukhari M, Lunt M, Harrison BJ, Scott DG, Symmons DP, Silman AJ: Erosions in inflammatory polyarthritis are symmetrical regardless of rheumatoid factor sta-

- tus: results from a primary care-based inception cohort of patients. *Rheumatology (Oxford)* 2002; 41:246–252.
Rec# 245
12. Emery P, Breedveld FC, Dougados M, Kalden JR, Schiff MH, Smolen JS: Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. *Ann Rheum Dis* 2002; 61:290–297.
Rec# 266
13. Saraux A, Berthelot JM, Chales G, Le Henaff C, Mary JY, Thorel JB, Hoang S, Dueymes M, Allain J, Devauchelle V, Baron D, Le Goff P, Youinou P: Value of laboratory tests in early prediction of rheumatoid arthritis. *Arthritis Rheum* 2002; 47:155–165.
Rec# 235
14. Bas S, Perneger TV, Seitz M, Tiercy JM, Roux-Lombard P, Guerne PA: Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors. *Rheumatology (Oxford)* 2002; 41:809–814.
Rec# 310
15. van Boekel MA, Vossenaar ER, van den Hoogen FH, van Venrooij WJ: Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. *Arthritis Res* 2002; 4:87–93.
Rec# 311
16. Machold KP, Stamm TA, Eberl GJ, Nell VK, Dunky A, Uffmann M, Smolen JS: Very recent onset arthritis – clinical, laboratory, and radiological findings during the first year of disease. *J Rheumatol* 2002; 29:2278–2287.
Rec# 293
17. van Zeben D, Hazes JM, Zwinderman AH, Vandenbroucke JP, Breedveld FC: The severity of rheumatoid arthritis: a 6-year followup study of younger women with symptoms of recent onset. *J Rheumatol* 94; 21:1620–1625.
Rec# 336
18. Wiles NJ, Dunn G, Barrett EM, Harrison BJ, Silman AJ, Symmons DP: One year followup variables predict disability 5 years after presentation with inflammatory polyarthritis with greater accuracy than at baseline. *J Rheumatol* 2000; 27:2360–2366.
Rec# 337
19. Lindqvist E, Saxne T, Geborek P, Eberhardt K: Ten year outcome in a cohort of patients with early rheumatoid arthritis: health status, disease process, and damage. *Ann Rheum Dis* 2002; 61:1055–1059.
Rec# 343
20. Bukhari MA, Wiles NJ, Lunt M, Harrison BJ, Scott DG, Symmons DP, Silman AJ: Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: Results from a large observational inception study. *Arthritis Rheum* 2003; 48:46–53.
Rec# 280
21. Wiles NJ, Lunt M, Barrett EM, Bukhari M, Silman AJ, Symmons DP, Dunn G: Reduced disability at five years with early treatment of inflammatory polyarthritis: results from a large observational cohort, using propensity models to adjust for disease severity. *Arthritis Rheum* 2001; 44:1033–1042.
Rec# 240
22. Mottonen T, Hannonen P, Korpela M, Nissila M, Kautiainen H, Ilonen J, Laasonen L, Kaipainen-Seppanen O, Franzen P, Helve T, Koski J, Gripenberg-Gahmberg M, Myllykangas-Luosujarvi R, Leirisalo-Repo M: Delay to institution of

- therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. *Arthritis Rheum* 2002; 46:894–898.
Rec# 228
23. Jansen LM, van der Horst-Bruinsma IE, van Schaardenburg D, Bezemer PD, Dijkmans BA: Predictors of radiographic joint damage in patients with early rheumatoid arthritis. *Ann Rheum Dis* 2001; 60:924–927.
Rec# 338
24. Jones G, Halbert J, Crotty M, Shanahan EM, Batterham M, Ahern M: The effect of treatment on radiological progression in rheumatoid arthritis: a systematic review of randomized placebo-controlled trials. *Rheumatology (Oxford)* 2003; 42:6–13.
Rec# 340
25. Egsmose C, Lund B, Borg G, Pettersson H, Berg E, Brodin U, Trang L: Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study. *J Rheumatol* 95; 22:2208–2213.
Rec# 86
26. Tsakonas E, Fitzgerald AA, Fitzcharles MA, Cividino A, Thorne JC, M’Seffar A, Joseph L, Bombardier C, Esdaile JM: Consequences of delayed therapy with second-line agents in rheumatoid arthritis: a 3 year followup on the hydroxychloroquine in early rheumatoid arthritis (HERA) study. *J Rheumatol* 2000; 27:623–629.
Rec# 88
27. Lard LR, Boers M, Verhoeven A, Vos K, Visser H, Hazes JM, Zwinderman AH, Schreuder GM, Breedveld FC, De Vries RR, van der Linde S, Zanelli E, Huizinga TW: Early and aggressive treatment of rheumatoid arthritis patients affects the association of HLA class II antigens with progression of joint damage. *Arthritis Rheum* 2002; 46:899–905.
Rec# 229
28. Mottonen T, Paimela L, Ahonen J, Helve T, Hannonen P, Leirisalo-Repo M: Outcome in patients with early rheumatoid arthritis treated according to the “saw-tooth” strategy. *Arthritis Rheum* 96; 39:996–1005.
Rec# 339
29. van Jaarsveld CH, Jacobs JW, van der Veen MJ, Blaauw AA, Kruize AA, Hofman DM, Brus HL, van Albada-Kuipers GA, Heurkens AH, ter Borg EJ, Haanen HC, van Booma-Frankfort C, Schenk Y, Bijlsma JW: Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial. On behalf of the Rheumatic Research Foundation Utrecht, The Netherlands. *Ann Rheum Dis* 2000; 59:468–477.
Rec# 89
30. Fries JF, Williams CA, Ramey D, Bloch DA: The relative toxicity of disease-modifying antirheumatic drugs. *Arthritis Rheum* 93; 36:297–306.
Rec# 341
31. Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, Spitz PW, Haga M, Kleinheksel SM, Cathey MA: The mortality of rheumatoid arthritis. *Arthritis Rheum* 94; 37:481–494.
Rec# 149

32. Peltomaa R, Paimela L, Kautiainen H, Leirisalo-Repo M: Mortality in patients with rheumatoid arthritis treated actively from the time of diagnosis. *Ann Rheum Dis* 2002; 61:889–894.
Rec# 342
33. Borg G, Allander E, Lund B: Auranofin improves outcome in early rheumatoid arthritis. *Journal of Rheumatology* 88; 15:1747–1754.
Rec# 84
34. Munro R, Hampson R, McEntegart A, Thomson EA, Madhok R, Capell H: Improved functional outcome in patients with early rheumatoid arthritis treated with intramuscular gold: results of a five year prospective study. *Ann Rheum Dis* 98; 57:88–93.
Rec# 81
35. Anderson JJ, Wells G, Verhoeven AC, Felson DT: Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. *Arthritis Rheum* 2000; 43:22–29.
Rec# 214
36. Fries JF, Williams CA, Morfeld D, Singh G, Sibley J: Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies. *Arthritis Rheum* 96; 39:616–622.
Rec# 83
37. Vliet Vlieland TP, Zwinderman AH, Vandenbroucke JP, Breedveld FC, Hazes JM: A randomized clinical trial of in-patient multidisciplinary treatment versus routine out-patient care in active rheumatoid arthritis. *Br J Rheumatol* 96; 35:475–482.
Rec# 308
38. Tijhuis GJ, Zwinderman AH, Hazes JM, Van Den Hout WB, Breedveld FC, Vliet Vlieland TP: A randomized comparison of care provided by a clinical nurse specialist, an inpatient team, and a day patient team in rheumatoid arthritis. *Arthritis Rheum* 2002; 47:525–531.
Rec# 307
39. Vliet Vlieland TP, Breedveld FC, Hazes JM: The two-year follow-up of a randomized comparison of in-patient multidisciplinary team care and routine out-patient care for active rheumatoid arthritis. *Br J Rheumatol* 97; 36:82–85.
Rec# 38
40. Holman HR, Lorig KR: Patient education: essential to good health care for patients with chronic arthritis. *Arthritis Rheum* 97; 40:1371–1373.
Rec# 40
41. Riemsma RP, Kirwan JR, Taal E, Rasker JJ: Patient education for adults with rheumatoid arthritis. *Cochrane Database.Syst.Rev.* 2002:CD003688.
Rec# 251
42. Sharpe L, Sensky T, Timberlake N, Ryan B, Brewin CR, Allard S: A blind, randomized, controlled trial of cognitive-behavioural intervention for patients with recent onset rheumatoid arthritis: preventing psychological and physical morbidity. *Pain* 2001; 89:275–283.
Rec# 298
43. Freeman K, Hammond A, Lincoln NB: Use of cognitive-behavioural arthritis education programmes in newly diagnosed rheumatoid arthritis. *Clin Rehabil* 2002; 16:828–836.
Rec# 313
44. Langer HE, Ehlebracht-Konig I, Mattussek S: [Quality standards of the German Society of Rheumatology for Rheumatologic Patient Education – preliminary re-

- port, discharged by the governing body and with consultation of the German Society of Rheumatology in September 1999]. *Z Rheumatol* 2000; 59:272–290.
Rec# 299
45. Ehlebracht-Konig I, Bonisch A: [Basic principles in rheumatologic patient education. Theoretical principles and didactic aspects]. *Z Rheumatol* 2002; 61:39–47.
Rec# 300
46. Langer HE, Ehlebracht-Konig I, Josenhans J: Evaluation des Patientenschulungskurses „chronische Polyarthritiis“. *Deutsche Rentenversicherung* 98:239–264.
Rec# 315
47. Helewa A, Bombardier C, Goldsmith CH, Menchions B, Smythe HA: Cost-effectiveness of inpatient and intensive outpatient treatment of rheumatoid arthritis. A randomized, controlled trial. *Arthritis Rheum* 89; 32:1505–1514.
Rec# 47
48. Lambert CM, Hurst NP, Forbes JF, Lochhead A, Macleod M, Nuki G: Is day care equivalent to inpatient care for active rheumatoid arthritis? Randomised controlled clinical and economic evaluation. *BMJ* 98; 316:965–969.
Rec# 48
49. Jessop JD, O’Sullivan MM, Lewis PA, Williams LA, Camilleri JP, Plant MJ, Coles EC: A long-term five-year randomized controlled trial of hydroxychloroquine, sodium aurothiomalate, auranofin and penicillamine in the treatment of patients with rheumatoid arthritis. *Br J Rheumatol* 98; 37:992–1002.
Rec# 80
50. van der Heide A, Jacobs JW, Bijlsma JW, Heurkens AH, van Booma-Frankfort C, van der Veen MJ, Haanen HC, Hofman DM, van Albada-Kuipers GA, ter Borg EJ, Brus HL, Dinant HJ, Kruize AA, Schenk Y: The effectiveness of early treatment with “second-line” antirheumatic drugs. A randomized, controlled trial. *Ann Intern Med* 96; 124:699–707.
Rec# 87
51. van der Heijde DM, van Riel PL, Nuver-Zwart IH, Gribnau FW, van de Putte LB: Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. *Lancet* 89; 1:1036–1038.
Rec# 93
52. Mottonen T, Hannonen P, Leirisalo-Repo M, Nissila M, Kautiainen H, Korpela M, Laasonen L, Julkunen H, Luukkainen R, Vuori K, Paimela L, Blafield H, Hakala M, Ilva K, Yli-Kerttula U, Puolakka K, Jarvinen P, Hakola M, Piirainen H, Ahonen J, Palvimaki I, Forsberg S, Koota K, Friman C: Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. *Lancet* 99; 353:1568–1573.
Rec# 131
53. Landewe RB, Goei The HS, van Rijthoven AW, Breedveld FC, Dijkmans BA: A randomized, double-blind, 24-week controlled study of low-dose cyclosporine versus chloroquine for early rheumatoid arthritis. *Arthritis Rheum* 94; 37:637–643.
Rec# 330
54. Zeidler HK, Kvien TK, Hannonen P, Wollheim FA, Forre O, Geidel H, Hafstrom I, Kaltwasser JP, Leirisalo-Repo M, Manger B, Laasonen L, Markert ER, Prestele H, Kurki P: Progression of joint damage in early active severe rheumatoid arthritis during 18 months of treatment: comparison of low-dose cyclosporin and par-enteral gold. *Br J Rheumatol* 98; 37:874–882.
Rec# 91

55. Proudman SM, Conaghan PG, Richardson C, Griffiths B, Green MJ, McGonagle D, Wakefield RJ, Reece RJ, Miles S, Adebajo A, Gough A, Helliwell P, Martin M, Huston G, Pease C, Veale DJ, Isaacs J, van der Heijde DM, Emery P: Treatment of poor-prognosis early rheumatoid arthritis. A randomized study of treatment with methotrexate, cyclosporin A, and intraarticular corticosteroids compared with sulfasalazine alone. *Arthritis Rheum* 2000; 43:1809–1819.
Rec# 138
56. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Genovese MC, Wasko MC, Moreland LW, Weaver AL, Markenson J, Finck BK: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. *N Engl J Med* 2000; 343:1586–1593.
Rec# 139
57. Menninger H, Herborn G, Sander O, Blechschmidt J, Rau R: A 36 month comparative trial of methotrexate and gold sodium thiomalate in the treatment of early active and erosive rheumatoid arthritis. *Br J Rheumatol* 98; 37:1060–1068.
Rec# 94
58. Rau R, Herborn G, Menninger H, Sangha O: Progression in early erosive rheumatoid arthritis: 12 month results from a randomized controlled trial comparing methotrexate and gold sodium thiomalate. *Br J Rheumatol* 98; 37:1220–1226.
Rec# 95
59. Haagsma CJ, van Riel PL, de Jong AJ, van de Putte LB: Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. *Br J Rheumatol* 97; 36:1082–1088.
Rec# 129
60. Dougados M, Combe B, Cantagrel A, Goupille P, Olive P, Schattenkirchner M, Meusser S, Paimela L, Rau R, Zeidler H, Leirisalo-Repo M, Peldan K: Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. *Ann Rheum Dis* 99; 58:220–225.
Rec# 130
61. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, van Zeben D, Dijkmans BA, Peeters AJ, Jacobs P, van den Brink HR, Schouten HJ: Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. *Lancet* 97; 350:309–318.
Rec# 137
62. The Australian Multicentre Clinical Trial Group: Sulfasalazine in early rheumatoid arthritis. *J Rheumatol* 92; 19:1672–1677.
Rec# 306
63. Hannonen P, Mottonen T, Hakola M, Oka M: Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study. *Arthritis Rheum* 93; 36:1501–1509.
Rec# 326
64. Suarez-Almazor ME, Spooner C, Belseck E: Penicillamine for rheumatoid arthritis. *Cochrane Database Syst Rev* 2000:CD001460.
Rec# 112
65. Suarez-Almazor ME, Spooner C, Belseck E: Azathioprine for rheumatoid arthritis. *Cochrane Database Syst Rev* 2000:CD001461.
Rec# 113

66. Suarez-Almazor ME, Belseck E, Shea B, Wells G, Tugwell P: Methotrexate for rheumatoid arthritis. *Cochrane Database Syst Rev* 2000:CD000957.
Rec# 275
67. Suarez-Almazor ME, Spooner CH, Belseck E, Shea B: Auranofin versus placebo in rheumatoid arthritis. *Cochrane Database Syst Rev* 2000:CD002048.
Rec# 276
68. Wells G, Haguenaer D, Shea B, Suarez-Almazor ME, Welch VA, Tugwell P: Cyclosporine for rheumatoid arthritis. *Cochrane Database Syst Rev* 2000:CD001083.
Rec# 277
69. Clark P, Tugwell P, Bennet K, Bombardier C, Shea B, Wells G, Suarez-Almazor ME: Injectible gold for rheumatoid arthritis. *Cochrane Database Syst Rev* 2000:CD000520.
Rec# 278
70. Suarez-Almazor ME, Belseck E, Shea B, Homik J, Wells G, Tugwell P: Antimalarials for rheumatoid arthritis. *Cochrane Database Syst Rev* 2000:CD000959.
Rec# 279
71. Suarez-Almazor ME, Belseck E, Shea B, Wells G, Tugwell P: Sulfasalazine for rheumatoid arthritis. *Cochrane Database Syst Rev* 2000:CD000958.
Rec# 282
72. Felson DT, Anderson JJ, Meenan RF: The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. *Arthritis Rheum* 90; 33:1449–1461.
Rec# 75
73. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F: Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. *Lancet* 2002; 359:1173–1177.
Rec# 223
74. Krause D, Schleusser B, Herborn G, Rau R: Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. *Arthritis Rheum* 2000; 43:14–21.
Rec# 291
75. Anderson RB, Needleman RD, Gatter RA, Andrews RP, Scarola JA: Patient outcome following inpatient vs outpatient treatment of rheumatoid arthritis. *J Rheumatol* 88; 15:556–560.
Rec# 46
76. Kirwan JR, Reeback JS: Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. *Br J Rheumatol* 86; 25:206–209.
Rec# 17
77. Pincus T, Brooks RH, Callahan LF: Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures. *Ann Intern Med* 94; 120:26–34.
Rec# 18
78. Wolfe F, Ross K, Hawley DJ, Roberts FK, Cathey MA: The prognosis of rheumatoid arthritis and undifferentiated polyarthritis syndrome in the clinic: a study of 1141 patients. *J Rheumatol* 93; 20:2005–2009.
Rec# 19
79. Mitchell DM, Spitz PW, Young DY, Bloch DA, McShane DJ, Fries JF: Survival, prognosis, and causes of death in rheumatoid arthritis. *Arthritis Rheum* 86; 29:706–714.
Rec# 20

80. Devlin J, Gough A, Huissoon A, Perkins P, Holder R, Reece R, Arthur V, Emery P: The acute phase and function in early rheumatoid arthritis. C-reactive protein levels correlate with functional outcome. *J Rheumatol* 97; 24:9–13.
Rec# 21
81. van der Heijde DM, van Riel PL, Van Leeuwen MA, van 't Hof MA, van Rijswijk MH, van de Putte LB: Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients. *Br J Rheumatol* 92; 31:519–525.
Rec# 22
82. ten Wolde S, Breedveld FC, Hermans J, Vandenbroucke JP, van de Laar MA, Markusse HM, Janssen M, van den Brink HR, Dijkmans BA: Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. *Lancet* 96; 347:347–352.
Rec# 97
83. Gotzsche PC, Hansen M, Stoltenberg M, Svendsen A, Beier J, Faarvang KL, Wangel M, Rydgren L, Halberg P, Juncker P, Andersen V, Hansen TM, Endahl L: Randomized, placebo controlled trial of withdrawal of slow-acting antirheumatic drugs and of observer bias in rheumatoid arthritis. *Scand J Rheumatol* 96; 25:194–199.
Rec# 98
84. Sokka T, Hannonen P: Utility of disease modifying antirheumatic drugs in “saw-tooth” strategy. A prospective study of early rheumatoid arthritis patients up to 15 years. *Ann Rheum Dis* 99; 58:618–622.
Rec# 99
85. Capell HA, Murphy EA, Hunter JA: Rheumatoid arthritis: workload and outcome over 10 years. *QJ Med* 91; 79:461–476.
Rec# 37
86. Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, Loew-Friedrich I, Oed C, Rosenburg R: Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. *Lancet* 99; 353:259–266.
Rec# 85
87. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, Fox R, Moreland L, Olsen N, Furst D, Caldwell J, Kaine J, Sharp J, Hurley F, Loew-Friedrich I: Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. *Arch Intern Med* 99; 159:2542–2550.
Rec# 96
88. Emery P, Breedveld FC, Lemmel EM, Kaltwasser JP, Dawes PT, Gomer B, Van den Bosch F, Nordstrom D, Bjorneboe O, Dahl R, Horslev-Petersen K, Rodriguez de la Serna A, Molloy M, Tikly M, Oed C, Rosenburg R, Loew-Friedrich I: A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. *Rheumatology (Oxford)* 2000; 39:655–665.
Rec# 114
89. Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE, Luggen ME, Keystone E, Weisman MH, Bensen WM, Kaine JL, Ruderman EM, Coleman P, Curtis DL, Kopp EJ, Kantor SM, Waltuck J, Lindsley HB, Markenson JA, Strand V, Crawford B, Fernando I, Simpson K, Bathon JM: Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of metho-

- trexate. A randomized, double-blind, placebo-controlled trial. *Ann Intern Med* 2002; 137:726–733.
Rec# 290
90. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. AT-TRACT Study Group. *Lancet* 99; 354:1932–1939.
Rec# 134
91. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. *N Engl J Med* 2000; 343:1594–1602.
Rec# 136
92. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. *Arthritis Rheum* 98; 41:1552–1563.
Rec# 219
93. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK: Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. *Arthritis Rheum* 2003; 48:35–45.
Rec# 284
94. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ: A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. *N Engl J Med* 99; 340:253–259.
Rec# 135
95. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, Weaver AL, Keystone EC, Furst DE, Mease PJ, Ruderman EM, Horwitz DA, Arkfeld DG, Garrison L, Burge DJ, Blosch CM, Lange ML, McDonnell ND, Weinblatt ME: Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. *Ann Intern Med* 99; 130:478–486.
Rec# 207
96. Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, Kremer J, Bear MB, Rich WJ, McCabe D: Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. *Arthritis Rheum* 2002; 46:614–624.
Rec# 227
97. Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, Nuki G, Pavelka K, Rau R, Rozman B, Watt I, Williams B, Aitchison R, McCabe D, Musicki P: Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. *Arthritis Rheum* 98; 41:2196–2204.
Rec# 283

98. Felson DT, Anderson JJ, Meenan RF: The efficacy and toxicity of combination therapy in rheumatoid arthritis. A meta-analysis. *Arthritis Rheum* 94; 37:1487–1491.
Rec# 125
99. Verhoeven AC, Boers M, Tugwell P: Combination therapy in rheumatoid arthritis: updated systematic review. *Br J Rheumatol* 98; 37:612–619.
Rec# 237
100. Landewe RB, Boers M, Verhoeven AC, Westhovens R, van de Laar MA, Markusse HM, van Denderen JC, Westedt ML, Peeters AJ, Dijkmans BA, Jacobs P, Boonen A, van der Heijde DM, van der Linde S: COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. *Arthritis Rheum* 2002; 46:347–356.
Rec# 232
101. Felson DT, Anderson JJ, Meenan RF: Use of short-term efficacy/toxicity trade-offs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials. *Arthritis Rheum* 92; 35:1117–1125.
Rec# 76
102. van Ede AE, Laan RF, Rood MJ, Huizinga TW, van de Laar MA, van Denderen CJ, Westgeest TA, Romme TC, de Rooij DJ, Jacobs MJ, de Boo TM, van der Wilt GJ, Severens JL, Hartman M, Krabbe PF, Dijkmans BA, Breedveld FC, van de Putte LB: Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. *Arthritis Rheum* 2001; 44:1515–1524.
Rec# 239
103. Ortiz Z, Shea B, Suarez-Almazor ME, Moher D, Wells GA, Tugwell P: The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials. *J Rheumatol* 98; 25:36–43.
Rec# 123
104. Beauparlant P, Papp K, Haraoui B: The incidence of cancer associated with the treatment of rheumatoid arthritis. *Semin Arthritis Rheum* 99; 29:148–158.
Rec# 101
105. Baecklund E, Ekbom A, Sparen P, Feltelius N, Klareskog L: Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. *BMJ* 98; 317:180–181.
Rec# 102
106. Asten P, Barrett J, Symmons D: Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. *J Rheumatol* 99; 26:1705–1714.
Rec# 103
107. Laan RF, Jansen TL, van Riel PL: Glucocorticosteroids in the management of rheumatoid arthritis. *Rheumatology (Oxford)* 99; 38:6–12.
Rec# 143
108. Gotsche PC, Johansen HK: Meta-analysis of short-term low dose prednisolone versus placebo and non-steroidal anti-inflammatory drugs in rheumatoid arthritis. *BMJ* 98; 316:811–818.
Rec# 252

109. van Gestel AM, Laan RF, Haagsma CJ, van de Putte LB, van Riel PL: Oral steroids as bridge therapy in rheumatoid arthritis patients starting with parenteral gold. A randomized double-blind placebo-controlled trial. *Br J Rheumatol* 95; 34:347–351.
Rec# 273
110. van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, Bijlsma JW: Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. *Ann Intern Med* 2002; 136:1–12.
Rec# 265
111. Kirwan JR: The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. *N Engl J Med* 95; 333:142–146.
Rec# 144
112. Million R, Kellgren JH, Poole P, Jayson MI: Long-term study of management of rheumatoid arthritis. *Lancet* 84; 1:812–816.
Rec# 145
113. Hickling P, Jacoby RK, Kirwan JR: Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group. *Br J Rheumatol* 98; 37:930–936.
Rec# 146
114. Baltzan MA, Suissa S, Bauer DC, Cummings SR: Hip fractures attributable to corticosteroid use. Study of Osteoporotic Fractures Group. *Lancet* 99; 353:1327.
Rec# 147
115. McDougall R, Sibley J, Haga M, Russell A: Outcome in patients with rheumatoid arthritis receiving prednisone compared to matched controls. *J Rheumatol* 94; 21:1207–1213.
Rec# 150
116. Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister LE, Zimmerman B, Kohler JA, Furst DE: Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. *Am J Med* 94; 96:115–123.
Rec# 151
117. Saag KG: Low-dose corticosteroid therapy in rheumatoid arthritis: balancing the evidence. *Am J Med* 97; 103:31S–39S.
Rec# 152
118. Seror P, Pluvinage P, d'Andre FL, Benamou P, Attuil G: Frequency of sepsis after local corticosteroid injection (an inquiry on 1160000 injections in rheumatological private practice in France). *Rheumatology (Oxford)* 99; 38:1272–1274.
Rec# 140
119. Weitoft T, Uddenfeldt P: Importance of synovial fluid aspiration when injecting intra-articular corticosteroids. *Ann Rheum Dis* 2000; 59:233–235.
Rec# 141
120. Chakravarty K, Pharoah PD, Scott DG: A randomized controlled study of post-injection rest following intraarticular steroid therapy for knee synovitis. *Br J Rheumatol* 94; 33:464–468.
Rec# 142
121. Furst DE: Are there differences among nonsteroidal antiinflammatory drugs? Comparing acetylated salicylates, nonacetylated salicylates, and nonacetylated nonsteroidal antiinflammatory drugs. *Arthritis Rheum* 94; 37:1–9.
Rec# 56

122. Brooks PM, Day RO: Nonsteroidal antiinflammatory drugs – differences and similarities. *N Engl J Med* 91; 324:1716–1725.
Rec# 57
123. Wolfe MM, Lichtenstein DR, Singh G: Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. *N Engl J Med* 99; 340:1888–1899.
Rec# 59
124. Fries JF, Spitz PW, Williams CA, Bloch DA, Singh G, Hubert HB: A toxicity index for comparison of side effects among different drugs. *Arthritis Rheum* 90; 33:121–130.
Rec# 60
125. Bleumink GS, Feenstra J, Sturkenboom MC, Stricker BH: Nonsteroidal anti-inflammatory drugs and heart failure. *Drugs* 2003; 63:525–534.
Rec# 318
126. Morris AJ, Madhok R, Sturrock RD, Capell HA, MacKenzie JF: Enteroscopic diagnosis of small bowel ulceration in patients receiving non-steroidal anti-inflammatory drugs. *Lancet* 91; 337:520.
Rec# 61
127. Rostom A, Wells G, Tugwell P, Welch V, Dube C, McGowan J: Prevention of NSAID-induced gastroduodenal ulcers. *Cochrane Database Syst Rev* 2000: CD002296.
Rec# 256
128. Chan FK, Sung JJ, Chung SC, To KF, Yung MY, Leung VK, Lee YT, Chan CS, Li EK, Woo J: Randomised trial of eradication of *Helicobacter pylori* before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. *Lancet* 97; 350:975–979.
Rec# 260
129. Chan FK, Chung SC, Suen BY, Lee YT, Leung WK, Leung VK, Wu JC, Lau JY, Hui Y, Lai MS, Chan HL, Sung JJ: Preventing recurrent upper gastrointestinal bleeding in patients with *Helicobacter pylori* infection who are taking low-dose aspirin or naproxen. *N Engl J Med* 2001; 344:967–973.
Rec# 261
130. Bluhm GB, Sharp JT, Tilley BC, Alarcon GS, Cooper SM, Pillemer SR, Clegg DO, Heyse SP, Trentham DE, Neuner R, Kaplan DA, Leisen JC, Buckley L, Duncan H, Tuttleman M, Li S, Fowler SE: Radiographic results from the Minocycline in Rheumatoid Arthritis (MIRA) Trial. *J Rheumatol* 97; 24:1295–302.
Rec# 119
131. Bensen W, Weaver A, Espinoza L, Zhao WW, Riley W, Paperiello B, Recker DP: Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: a randomized, controlled comparison with placebo and naproxen. *Rheumatology* 2002; 41:1008–1016.
Rec# 321
132. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowitz JB, Verburg KM, Geis GS: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. *JAMA* 2000; 284:1247–1255.
Rec# 71
133. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ: Comparison of

- upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. *N Engl J Med* 2000; 343:1520–1528.
Rec# 72
134. Garner S, Fidan D, Frankish R, Judd M, Towheed T, Wells G, Tugwell P: Rofecoxib for the treatment of rheumatoid arthritis. *Cochrane Database Syst Rev* 2002:CD003685.
Rec# 253
135. Garner S, Fidan D, Frankish R, Judd M, Towheed T, Wells G, Tugwell P: Celecoxib for rheumatoid arthritis. *Cochrane Database Syst Rev* 2002:CD003831
Rec# 257
136. Leese PT, Hubbard RC, Karim A, Isakson PC, Yu SS, Geis GS: Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. *J Clin Pharmacol* 2000; 40:124–132.
Rec# 258
137. Van Hecken A, Schwartz JI, Depre M, De LI, Dallob A, Tanaka W, Wynants K, Buntinx A, Arnout J, Wong PH, Ebel DL, Gertz BJ, De Schepper PJ: Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. *J Clin Pharmacol* 2000; 40:1109–1120.
Rec# 259
138. Chan FK, Hung LC, Suen BY, Wu JC, Lee KC, Leung VK, Hui AJ, To KF, Leung WK, Wong VW, Chung SC, Sung JJ: Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. *N Engl J Med* 2002; 347:2104–2110.
Rec# 272
139. Swan SK, Rudy DW, Lasseter KC, Ryan CF, Buechel KL, Lambrecht LJ, Pinto MB, Dilzer SC, Obrda O, Sundblad KJ, Gumbs CP, Ebel DL, Quan H, Larson PJ, Schwartz JI, Musliner TA, Gertz BJ, Brater DC, Yao SL: Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial. *Ann Intern Med* 2000; 133:1–9.
Rec# 67
140. Ahmad SR, Kortepeter C, Brinker A, Chen M, Beitz J: Renal failure associated with the use of celecoxib and rofecoxib. *Drug Saf* 2002; 25:537–544.
Rec# 319
141. LeLorier J, Bombardier C, Burgess E, Moist L, Wright N, Cartier P, Huckell V, Hunt R, Nawar T, Tobe S: Practical considerations for the use of nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 inhibitors in hypertension and kidney disease. *Can J Cardiol* 2002; 18:1301–1308.
Rec# 320
142. Langman MJ, Weil J, Wainwright P, Lawson DH, Rawlins MD, Logan RF, Murphy M, Vessey MP, Colin-Jones DG: Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. *Lancet* 94; 343:1075–1078.
Rec# 63
143. Garcia Rodriguez LA, Jick H: Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. *Lancet* 94; 343:769–772.
Rec# 64

144. Hernandez-Diaz S, Rodriguez LA: Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. *Arch Intern Med* 2000; 160:2093–2099.
Rec# 334
145. Huskisson EC: Simple analgesics for arthritis. *Br Med J* 74; 4:196–200.
Rec# 51
146. Hardin JG, Kirk KA: Comparative effectiveness of five analgesics for the pain of rheumatoid synovitis. *J Rheumatol* 79; 6:405–412.
Rec# 52
147. Seideman P, Melander A: Equianalgesic effects of paracetamol and indomethacin in rheumatoid arthritis. *Br J Rheumatol* 88; 27:117–122.
Rec# 55
148. Bell MJ, Lineker SC, Wilkins AL, Goldsmith CH, Badley EM: A randomized controlled trial to evaluate the efficacy of community based physical therapy in the treatment of people with rheumatoid arthritis. *J Rheumatol* 98; 25:231–237.
Rec# 169
149. Van den Ende CHM, Vliet Vleiland TP, Munneke M, Hazes JM: Dynamic exercise therapy for rheumatoid arthritis (Cochrane Review). *The Cochrane Library* 2002:CD000322
Rec# 170
150. Bostrom C, Harms-Ringdahl K, Karreskog H, Nordemar R: Effects of static and dynamic shoulder rotator exercises in women with rheumatoid arthritis: a randomised comparison of impairment, disability, handicap, and health. *Scand J Rheumatol* 98; 27:281–290.
Rec# 171
151. Ahern M, Nicholls E, Simionato E, Clark M, Bond M: Clinical and physiological effects of hydrotherapy in rheumatic diseases. *Clin Rehab* 95; 9:204–212.
Rec# 172
152. Hall J, Skevington SM, Maddison PJ, Chapman K: A randomized and controlled trial of hydrotherapy in rheumatoid arthritis. *Arthritis Care Res* 96; 9:206–215.
Rec# 173
153. Verhagen AP, de Vet HC, de Bie RA, Kessels AG, Boers M, Knipschild PG: Taking baths: the efficacy of balneotherapy in patients with arthritis. A systematic review. *J Rheumatol* 97; 24:1964–1971.
Rec# 174
154. Brosseau LU, Pelland LU, Casimiro LY, Robinson VI, Tugwell PE, Wells GE: Electrical stimulation for the treatment of rheumatoid arthritis. *Cochrane Database Syst Rev* 2002:CD003687.
Rec# 285
155. Brosseau L, Welch V, Wells G, de Bie R, Gam A, Harman K, Morin M, Shea B, Tugwell P: Low level laser therapy (classes I, II and III) in the treatment of rheumatoid arthritis. *Cochrane Database Syst Rev* 2000:CD002049.
Rec# 292
156. Robinson V, Brosseau L, Casimiro L, Judd M, Shea B, Wells G, Tugwell P: Thermotherapy for treating rheumatoid arthritis. *Cochrane Database Syst Rev* 2002:CD002826.
Rec# 296
157. Casimiro L, Brosseau L, Robinson V, Milne S, Judd M, Well G, Tugwell P, Shea B: Therapeutic ultrasound for the treatment of rheumatoid arthritis. *Cochrane*

- Database Syst Rev* 2002:CD003787.
Rec# 295
158. Deutsche Gesellschaft für Rheumatologie (Hrsg.): Qualitätssicherung in der Rheumatologie. Loseblattsammlung Teillieferung 3. Steinkopff, Darmstadt 2004
Rec# 316
159. Steultjens EM, Dekker J, Bouter LM, van Schaardenburg D, Van Kuyk MA, Van den Ende CH: Occupational therapy for rheumatoid arthritis: A systematic review. *Arthritis Rheum* 2002; 47:672–685.
Rec# 270
160. Haugen M, Fraser D, Forre O: Diet therapy for the patient with rheumatoid arthritis? *Rheumatology (Oxford)* 99; 38:1039–1044.
Rec# 193
161. Kjeldsen-Kragh J, Haugen M, Borchgrevink CF, Laerum E, Eek M, Mowinkel P, Hovi K, Forre O: Controlled trial of fasting and one-year vegetarian diet in rheumatoid arthritis. *Lancet* 91; 338:899–902.
Rec# 194
162. Fortin PR, Lew RA, Liang MH, Wright EA, Beckett LA, Chalmers TC, Sperling RI: Validation of a meta-analysis: the effects of fish oil in rheumatoid arthritis. *J Clin Epidemiol.* 95; 48:1379–1390.
Rec# 195
163. Little C, Parsons T: Herbal therapy for treating rheumatoid arthritis. *Cochrane Database Syst Rev* 2001:CD002948.
Rec# 271
164. Sangha O, Stucki G: [Vitamin E in therapy of rheumatic diseases]. *Z Rheumatol* 98; 57:207–214.
Rec# 317
165. Tarp U, Overvad K, Thorling EB, Graudal H, Hansen JC: Selenium treatment in rheumatoid arthritis. *Scand J Rheumatol* 85; 14:364–368.
Rec# 162
166. Linde K, Clausius N, Ramirez G, Melchart D, Eitel F, Hedges LV, Jonas WB: Are the clinical effects of homeopathy placebo effects? A meta-analysis of placebo-controlled trials. *Lancet* 97; 350:834–843.
Rec# 153
167. Casimiro L, Brosseau L, Milne S, Robinson V, Wells G, Tugwell P: Acupuncture and electroacupuncture for the treatment of RA. *Cochrane Database Syst Rev* 2002:CD003788.
Rec# 312
168. Ernst E: Evidence-based complementary medicine: a contradiction in terms? *Ann Rheum Dis* 99; 58:69–70.
Rec# 163
169. Lautenschläger J, Mau W, Kohlmann T, Raspe HH, Struve F, Brückle W, Zeidler H: Vergleichende Evaluation einer deutschen Version des Health Assessment Questionnaires (HAQ) und des Funktionsfragebogens Hannover (FFbH). *Z Rheumatol* 97; 56:144–155.
Rec# 331
170. Bruhlmann P, Stucki G, Michel BA: Evaluation of a German version of the physical dimensions of the Health Assessment Questionnaire in patients with rheumatoid arthritis. *J Rheumatol* 94; 21:1245–1249.
Rec# 335

171. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, Katz LM, Lightfoot R Jr, Paulus H, Strand V: American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. *Arthritis Rheum* 95; 38:727–735.
Rec# 198
172. van Gestel AM, Prevoo ML, van't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL: Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. *Arthritis Rheum* 96; 39:34–40.
Rec# 199
173. Sharp JT: An overview of radiographic analysis of joint damage in rheumatoid arthritis and its use in metaanalysis. *J Rheumatol* 2000; 27:254–260.
Rec# 201
174. Kirwan JR: Using the Larsen index to assess radiographic progression in rheumatoid arthritis. *J Rheumatol* 2000; 27:264–268.
Rec# 202
175. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Wasko MC, Moreland LW, Weaver AL, Markenson J, Cannon GW, Spencer-Green G, Finck BK: Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. *Arthritis Rheum* 2002; 46:1443–1450.
Rec# 333
176. Lorig KR, Mazonson PD, Holman HR: Evidence suggesting that health education for self-management in patients with chronic arthritis has sustained health benefits while reducing health care costs. *Arthritis Rheum* 93; 36:439–446.
Rec# 44
177. Haar D, Solvkaer M, Unger B, Rasmussen KJ, Christensen L, Hansen TM: A double-blind comparative study of hydroxychloroquine and dapsone, alone and in combination, in rheumatoid arthritis. *Scand J Rheumatol* 93; 22:113–118.
Rec# 304
178. Gibson T, Emery P, Armstrong RD, Crisp AJ, Panayi GS: Combined D-penicillamine and chloroquine treatment of rheumatoid arthritis – a comparative study. *Br J Rheumatol* 87; 26:279–284.
Rec# 303
179. A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA Study. *Am J Med* 98:156–168.
Rec# 105
180. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, Martin Mola E, Pavelka K, Sany J, Settas L, Wajdula J, Pedersen R, Fatenejad S, Sanda M: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. *Lancet* 2004; 363: 675–681
181. Nyhall-Wahlin BM, Jacobsson LT, Petersson IF, Turesson C: Smoking is a strong risk factor for rheumatoid nodules in early rheumatoid arthritis. *Ann Rheum Dis* 2006; 65(5):601–606.
182. Puolakka K, Kautiainen H, Mottonen T, Hannonen P, Korpela M, Hakala M et al: Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. *Arthritis Rheum* 2005; 52(1):36–41.

183. Hammond A, Young A, Kidao R: A randomised controlled trial of occupational therapy for people with early rheumatoid arthritis. *Ann Rheum Dis* 2004; 63(1):23–30.
184. St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P et al: Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. *Arthritis Rheum* 2004; 50(11):3432–3443.
185. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van VR et al: The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. *Arthritis Rheum* 2006; 54(1):26–37.
186. Gorman JD: Smoking and rheumatoid arthritis: another reason to just say no. *Arthritis Rheum* 2006; 54(1):10–13.
187. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van ZD, Kerstens PJ, Hazes JM et al: Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. *Arthritis Rheum* 2005; 52(11):3381–3390.
188. Korpela M, Laasonen L, Hannonen P, Kautiainen H, Leirisalo-Repo M, Hakala M et al: Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study. *Arthritis Rheum* 2004; 50(7):2072–2081.
189. Nell VP, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS: Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. *Rheumatology (Oxford)* 2004; 43(7):906–914.
190. Hider SL, Silman AJ, Bunn D, Manning S, Symmons DP, Lunt M. Comparing the long term clinical outcome between methotrexate and sulfasalazine prescribed as the first DMARD in patients with inflammatory polyarthritis. *Ann Rheum Dis* 2006.
191. Le L, X, Berthelot JM, Cantagrel A, Combe B, De BM, Fautrel B et al: Clinical practice decision tree for the choice of the first disease modifying antirheumatic drug for very early rheumatoid arthritis: a 2004 proposal of the French Society of Rheumatology. *Ann Rheum Dis* 2006; 65(1):45–50.
192. Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A et al: Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. *Arthritis Rheum* 2005; 52(1):27–35.
193. Smolen JS, Aletaha D, Keystone E: Superior efficacy of combination therapy for rheumatoid arthritis: fact or fiction? *Arthritis Rheum* 2005; 52(10):2975–2983.
194. Choy EH, Smith C, Dore CJ, Scott DL: A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. *Rheumatology (Oxford)* 2005; 44(11):1414–1421.
195. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R et al: Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. *Lancet* 2004; 364(9430):263–269.

196. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. *JAMA* 2006; 295(19):2275–2285.
197. Listing J, Strangfeld A, Kary S, Rau R, von HU, Stoyanova-Scholz M et al: Infections in patients with rheumatoid arthritis treated with biologic agents. *Arthritis Rheum* 2005; 52(11):3403–3412.
198. Baecklund E, Iliadou A, Askling J, Ekblom A, Backlin C, Granath F et al: Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. *Arthritis Rheum* 2006; 54(3):692–701.
199. Svensson B, Boonen A, Albertsson K, van der HD, Keller C, Hafstrom I: Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. *Arthritis Rheum* 2005; 52(11):3360–3370.
200. Wassenberg S, Rau R, Steinfeld P, Zeidler H: Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. *Arthritis Rheum* 2005; 52(11):3371–3380.
201. van AJ, Lard LR, le CS, Hazes JM, Breedveld FC, Huizinga TW: Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis. *Ann Rheum Dis* 2004; 63(3):274–279.
202. Matsumoto AK, Melian A, Mandel DR, McIlwain HH, Borenstein D, Zhao PL et al: A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. *J Rheumatol* 2002; 29(8):1623–1630.
203. Collantes E, Curtis SP, Lee KW, Casas N, McCarthy T, Melian A et al: A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273]. *BMC Fam Pract* 2002; 3:10.
204. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K et al: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. *N Engl J Med* 2005; 352(11):1092–1102.
205. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P et al: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. *N Engl J Med* 2005; 352(11):1071–1080.
206. Johnsen SP, Larsson H, Tarone RE, McLaughlin JK, Norgard B, Friis S et al: Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. *Arch Intern Med* 2005; 165(9):978–984.
207. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. *BMJ* 2005; 330(7504):1366.
208. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C: Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. *BMJ* 2006; 332(7553):1302–1308..
209. Steultjens EM, Dekker J, Bouter LM, van SD, van Kuyk MA, van den Ende CH. Occupational therapy for rheumatoid arthritis. *Cochrane Database Syst Rev* 2004; (1):CD003114.

210. Lindqvist E, Eberhardt K, Bendtzen K, Heinegard D, Saxne T: Prognostic laboratory markers of joint damage in rheumatoid arthritis. *Ann Rheum Dis* 2005; 64(2):196–201.
211. van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW: Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. *Arthritis Res Ther* 2005; 7(5):R949–R958.
212. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL et al: Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. *Arthritis Rheum* 2004; 50(3):709–715.
213. Kastbom A, Strandberg G, Lindroos A, Skogh T: Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). *Ann Rheum Dis* 2004; 63(9):1085–1089.
214. Berglin E, Johansson T, Sundin U, Jidell E, Wadell G, Hallmans G et al: Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. *Ann Rheum Dis* 2006; 65(4):453–458.
215. Nielen MM, van SD, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH et al: Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. *Arthritis Rheum* 2004; 50(2):380–386.
216. Nell VP, Machold KP, Stamm TA, Eberl G, Heinzl H, Uffmann M et al: Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. *Ann Rheum Dis* 2005; 64(12):1731–1736.
217. Ronnelid J, Wick MC, Lampa J, Lindblad S, Nordmark B, Klareskog L et al: Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. *Ann Rheum Dis* 2005; 64(12):1744–1749.
218. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H et al: Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. *Arthritis Rheum* 2003; 48(10):2741–2749.
219. Kirwan JR: The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. *N Engl J Med* 1995; 333(3):142–146.